Section Arrow
SYRE.NASDAQ
- Spyre Therapeutics
Quotes are at least 15-min delayed:2026/02/24 22:22 EST
Regular Hours
Last
 43.45
-0.73 (-1.65%)
Day High 
44.81 
Prev. Close
44.18 
1-M High
45.76 
Volume 
636.49K 
Bid
40.01
Ask
46.05
Day Low
43.05 
Open
44.17 
1-M Low
30.92 
Market Cap 
3.43B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 37.07 
20-SMA 35.06 
50-SMA 33.62 
52-W High 45.76 
52-W Low 10.91 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.32/-4.70
Enterprise Value
3.43B
Balance Sheet
Book Value Per Share
3.86
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
BRTXBioRestorative Therapies0.2695+0.0665+32.76%-- 
EDSAEdesa Biotech1.52+0.621+69.08%-- 
IBRXImmunityBio11.545+1.725+17.57%-- 
GOSSGossamer Bio0.4154-0.00515-1.22%-- 
LRMRLarimar Therapeutics3.69+0.88+31.32%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting 47, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.